νλ€λΌν
νλ€λΌνμ μ§μμ± **ν¬μ€ν¬λμμ€ν λΌμ 5 (PDE5) μ΅μ μ **λ‘, μμνμμλ μ£Όλ‘ λ°λ €κ²¬μ **νλλ§₯ κ³ νμ(PAH)** κ΄λ¦¬μ μ¬μ©λ©λλ€. * **μμ μμ **: μ€λ°λνμ λΉν΄ λ°κ°κΈ°κ° ν¨μ¬ κΈΈμ΄ 1μΌ 1ν λλ κ²©μΌ ν¬μ¬κ° κ°λ₯νλ―λ‘ λ³΄νΈμμ μμλλ₯Ό ν¬κ² ν₯μμν΅λλ€. * μ°μ¬μ€ μλ ₯μ΄ λκ² μ μ§λ λ κΈ°μ‘΄ μ¬λΆμ μΉλ£μ (μ: νΌλͺ¨λ²€λ¨, μ΄λ¨μ , ACE μ΅μ μ )μ ν¨κ» 보쑰 μλ²μΌλ‘ μμ£Ό μ¬μ©λ©λλ€. * *μ°Έκ³ *: νμ¬ μμνμ μμ λ°μ΄ν° λ° λ¬Ένμ λ§€μ° μ νμ μ΄λ©° μ½κ°κ° λ§€μ° λΉμ μ μμ΅λλ€.
μμ© κΈ°μ : Tadalafil selectively inhibits **cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5)**. **Mechanism Pathway**: Endothelial stimulation β **Nitric Oxide (NO)** release β Activation of **guanylate cyclase** β Increased **cGMP** production. Normally, **PDE5** (found in pulmonary vascular smooth muscle, corpus cavernosum, and platelets) degrades cGMP. By inhibiting PDE5, tadalafil prevents this degradation. Increased intracellular **cGMP** β Decreased intracellular calcium in smooth muscle cells β **Relaxation of pulmonary vascular smooth muscle** β **Vasodilation** and significant reduction of pulmonary arterial pressure (PAP).
λλ¬Ό μ’ λ³ μ©λ
- Pulmonary arterial hypertension Β· 1 mg/kg PO q48h (every other day) Β· PO Β· q48h Β· Added to background treatment (furosemide, spironolactone, benazepril, dexamethasone, oxygen).
- Pulmonary arterial hypertension Β· 1 mg/kg PO once daily Β· PO Β· q24h
μ©λμ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μ°Έκ³ μλ£μ λλ€. νμ μ΅μ λΌλ²¨κ³Ό κ°λ³ νμμ λν΄ νμΈνμμμ€.
ν¬μ¬ κ²½λ‘
κΈκΈ°
- Concurrent use of any form of organic nitrates (regularly or intermittently)
- Serious hypersensitivity to tadalafil
μ΄μλ°μ
- Cutaneous flushing of the inguinal region
- Gastrointestinal upset (dyspepsia, nausea)
- Decreased neutrophils and platelets (observed at 4X-18X human equivalent doses; reversible)
- Hypotension (especially if combined with other vasodilators)
- Myalgia or back pain (reported in humans)
- Headache or nasal congestion (reported in humans)
μ½λ¬Ό μνΈμμ©
- Alpha-adrenergic blockers (e.g., phentolamine, phenothiazines, phenoxybenzamine) Β· May increase hypotensive effects
- Amlodipine Β· Potential to increase hypotensive effects
- Antihypertensive / Hypotensive drugs Β· Potentially could increase hypotensive effects
- Azole antifungals (ketoconazole, itraconazole) Β· May reduce tadalafil metabolism and increase AUC
- Cimetidine Β· May reduce tadalafil metabolism and increase AUC
- Erythromycin, Clarithromycin Β· May reduce tadalafil metabolism and increase AUC
- Nitrates (e.g., Nitroglycerin, Isosorbide) Β· Significant potentiation of vasodilatory effects; life-threatening hypotension possible
- Nitroprusside sodium Β· Significant potentiation of vasodilatory effects; life-threatening hypotension possible
- Phenobarbital Β· May decrease tadalafil concentrations
- Rifampin Β· May decrease tadalafil concentrations
λͺ¨λν°λ§
- Clinical efficacy (improved syncope, cough, respiratory effort)
- Pulmonary artery pressure (via echocardiography)
- Systemic blood pressure
- Adverse effects (GI upset, flushing)
κ³Όμ©λ
Little information is available for veterinary species. In humans, single doses up to 500 mg and multiple daily doses up to 100 mg produced adverse reactions similar to those seen at lower doses. Overdoses in animals are expected to mirror the drug's adverse effect profile (e.g., severe hypotension, tachycardia, flushing). **Treat supportively** and contact an animal poison control center for guidance.
VetSheet μ½λ¬Ό λ νΌλ°μ€λ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μμ¬κ²°μ 보쑰 λꡬμ΄λ©°, μ λ¬Έμ νλ¨μ΄λ μ μ‘°μ¬μ μ΅μ λΌλ²¨μ λμ νμ§ μμ΅λλ€.